Predictive Oncology Acquires zPREDICTA, Inc.
EAGAN, Minn., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology, (POAI), a knowledge-driven company focused on applying artificial intelligence (AI) to develop personalized cancer therapies, today announced the acquisition of zPREDICTA, a company pioneering tumor-specific in vitro 3D cell culture models for drug discovery and development. The acquisition immediately adds a new anticipated revenue stream to Predictive Oncology and contributes to the company's larger mission of supporting the development of new cancer therapies from drug discovery through regulatory approval. Based on zPREDICTA's historical operating results and anticipated synergies, Predictive Oncology believes the ac
